Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 placebo-controlled study of subcutaneous amlitelimab monotherapy in adults with severe alopecia areata
CTR20242954Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of amlitelimab in alopecia areata, sponsored by Sanofi. Started Nov 2024; status: terminated.
02
Drugs
amlitelimab
03
Conditions
alopecia areata
Beyond the preview
Go deeper on CTR20242954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242954.